Bottom line
Is TMED a good fund? The bottom line
TMED is an actively managed health care sector ETF from T. Rowe Price.
It charges 0.44% — about $44 a year on every $10,000 invested, cheaper than 85% of health care sector funds we track.
With $23.0 million in net assets and 102 holdings, its largest position is Eli Lilly & Co (16.7%) and the top 10 make up 47.5% of the portfolio.
What stands out
- Low cost: cheaper than 85% of health care sector peers
What to watch
- Small fund ($23.0 million) — small funds are likelier to close
Updated Nov 19, 2026
What TMED invests in
The fund seeks long-term capital appreciation.
The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of health care companies. The fund defines health care companies as companies engaged in health care innovations, such as developing new and effective therapies; pharmaceuticals; biotechnology; life sciences tools and services; managed health care; and/or health care equipment, supplies, providers, services, distributors, and facilities. The fund references the MSCI GICS (Global Industry Classification Standard) Health Care sector to identify such companies. Any derivatives that provide exposure to the investment focus suggested by the funds name, or to one or more market risk factors associated with the investment focus suggested by the funds name, are counted (as applicable) toward compliance with the funds 80% investment policy. As a fundamental policy, the fund…
From the fund's prospectus (filed Feb 25, 2026).
What TMED costs
On a $10,000 investment, TMED's 0.44% expense ratio costs about $44 a year. The prospectus estimates $555 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
TMED top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 16.71% |
| 2 | Unitedhealth Group Inc | 6.52% |
| 3 | Gilead Sciences Inc | 4.44% |
| 4 | Thermo Fisher Scientific Inc | 4.11% |
| 5 | Danaher Corp | 2.96% |
| 6 | Cencora Inc | 2.75% |
| 7 | Agilent Technologies Inc | 2.61% |
| 8 | Alnylam Pharmaceuticals Inc | 2.60% |
| 9 | Intuitive Surgical Inc | 2.43% |
| 10 | Insulet Corp | 2.38% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 47.5% of the fund. See all top 25 holdings and asset mix →